Biognosys: Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

Biognosys' proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensingBy offering the combination of NULISA affinity-based assays and TrueDiscovery® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry's most comprehensive solutions for plasma proteomicsSpectronaut® workflows for high-performance computing environments, post-translational modifications, and protein-turnover profiling elevate the scale and scope of DIA proteomicsSpectroDive 12 delivers breakthrough performance for targeted proteomics workflows, with novel features for in-silico panel development, flexible quantification, refined precision, and enhanced sensitivityZURICH, Switzerland and NEWTON, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany. The company will be highlighting major scientific and technological advances for its proprietary proteomics research services and software solutions with two oral presentations, eight scientific posters, one sponsored seminar, and two invited seminar talks.Industry-Leading Plasma Solutions across All Research NeedsWith an oral presentation entitled "High-throughput and deep plasma proteomics allows the classification of cancer types", Biognosys, in collaboration with the University of Fribourg, will showcase the robustness and power of deriving biological insights from plasma samples using its proprietary P2 Plasma Enrichment System. The P2 technology delivers up to 7,000 protein identifications and quantifications in human plasma, using Biognosys' breakthrough offering on the Bruker timsTOF® HT platform, setting new standards for industry-leading throughput, depth and affordability. A lower-throughput workflow for more in-depth biological profiling in smaller-scale studies can quantify up to 9,000 proteins in human plasma.The P2 technology is based on a proprietary, single-well, single particle-type workflow that combines optimized surface chemistry with a novel buffer system that stabilizes the labile protein corona that forms around particles in blood plasma. The P2 method achieves the highest ...Full story available on Benzinga.com